Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit.

NCT03455322 is registered in ClinicalTrials.gov with National Hepatology & Tropical Medicine Research Institute as lead sponsor.

NCT NCT03455322
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03455322 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit.
Lead sponsor
National Hepatology & Tropical Medicine Research Institute
Phase
Phase 4
Overall status
Completed
Start date
August 15, 2018
Completion date
July 10, 2020
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment in hepatorenal syndrome